BioSpace News Archive

Drug Development

BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC

Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading IO conference SITC

November 2, 2018
·
5 min read
Forbion Leads €17M Series C Financing of Omeicos Therapeutics

Forbion invests €12.5m from its recently launched Forbion IV fund

November 2, 2018
·
4 min read
Business

Leading Hepatorenal Expert Joins Mallinckrodt’s Scientific Advisory Council

Mallinckrodt plc today announced the addition of a new member to its Scientific Advisory Council (SAC).

November 2, 2018
·
2 min read
Business

Elanco Announces Collaboration Agreement with Novozymes for Nutritional Health Innovation

The collaboration furthers Elanco’s commitment to antibiotic stewardship and offering alternatives to unmet needs.

November 2, 2018
·
4 min read
Business

ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results

Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine with KEYTRUDA® Reported at ESMO

November 2, 2018
·
11 min read
BioForest

Red Cross Says ‘Turn and Test’ as Daylight Saving Time Ends; Turn Your Clocks Back, Test Smoke Alarms This Weekend

Working Smoke Alarms Cut the Risk of Dying in a Home Fire

November 2, 2018
·
3 min read
Deals

Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss ZULRESSO™ (brexanolone) Injection for the Treatment of Postpartum Depression

Sage Therapeutics today announced that NASDAQ has halted trading of the company’s common stock.

November 2, 2018
·
1 min read
Pharm Country

Celgene Corporation to Webcast at Upcoming November and December 2018 Investor Events

Celgene Corporation plans to present at two upcoming investor events where Celgene management will provide an overview of the Company.

November 2, 2018
·
2 min read
Business

GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements

Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe, Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment

November 2, 2018
·
9 min read
DNAe: Breakthrough in Rapid Diagnostic for Antimicrobial Resistance

DNAe achieves major milestone in a novel clinical sequencing platform, successfully completing the first phase of its $51.9 million contract with US government’s BARDA

November 2, 2018
·
6 min read